优质医用同位素钪-44在鲁实现国内首次量产

Core Viewpoint - The successful domestic mass production of Scandium-44 in China marks a significant advancement in the development of new PET imaging agents for precise tumor diagnosis, indicating a promising industry outlook. Group 1: Production Achievement - The research team at the Jinan Institute of Nuclear Technology has achieved the first domestic mass production of Scandium-44, with an activity level of 100 milliCurie and a nuclear purity greater than 99% [2] - This production reduces the gap with foreign counterparts, which have been mass-producing Scandium-44 for over a decade [2] Group 2: Technical Process - The production process of Scandium-44 is complex, previously only achievable at the laboratory level in China, while foreign countries had already advanced to drug development and clinical trials [2] - The team innovated the target preparation process and independently developed the purification workflow, conducting over 50 full-process experiments and thousands of data simulations over 700 days [2][4] Group 3: Advantages of Scandium-44 - Scandium-44 is considered a superior imaging agent compared to commonly used isotopes like Fluorine-18 and Gallium-68 due to its longer half-life of approximately 4.04 hours, allowing for more flexible production and distribution [3] - Its lower positron energy results in higher imaging quality, and it can easily be labeled with various types of drugs, including peptides, antibodies, and small molecules [3] Group 4: Future Prospects - The production process developed is compatible with most accelerators used in hospitals, and the low raw material costs suggest that more hospitals and research institutions may engage in the development of Scandium-44-based drugs [4]